Biomarkers of Antidepressant Resistance

NCT ID: NCT03118193

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-16

Study Completion Date

2021-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According to the WHO, major depressive disorders have become the second worldwide cause of disability. Treatment, long-term medication, leads to frequent resistance (up to 40%).

Establishing a cerebral molecular signature of depression is not feasible in humans (need for cerebral samples). The alternative is to use peripheral biological samples (blood, urine, saliva).

Metabolomic is the integrated and quantitative study of all the metabolites of a biological system. This aims to define the metabolic status of an organism for a particular condition.

Metabolites are derived from biological extracts (cells, tissues, serum, plasma, urine, etc.) and are detected by:

* liquid or gas chromatography coupled to mass spectrometry (LC-MS, GC-MS),
* proton nuclear magnetic resonance (1 H-NMR). The biomarkers resulting from these studies have become important diagnostic criteria, measured objectively and evaluated as indicators of a normal or pathological state, or even predictors of treatment efficacy.

This approach allows the discovery of biomarkers that best describe the status of a disease for better understanding and are usable in a context of individualized medicine, with effects on clinical practice and management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

depression antidepressant resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Depressive patient

olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces

Group Type EXPERIMENTAL

olfactive tests

Intervention Type OTHER

olfactive tests: odor identification, odor discrimination and olfactory threshold

blood test

Intervention Type BIOLOGICAL

one sample of 4mL

Collection of faeces

Intervention Type BIOLOGICAL

Collection of faeces by patient at home - optional

Tissue Pulsatility imaging

Intervention Type DEVICE

Ultrasound exploration of brain pulsatility - optional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

olfactive tests

olfactive tests: odor identification, odor discrimination and olfactory threshold

Intervention Type OTHER

blood test

one sample of 4mL

Intervention Type BIOLOGICAL

Collection of faeces

Collection of faeces by patient at home - optional

Intervention Type BIOLOGICAL

Tissue Pulsatility imaging

Ultrasound exploration of brain pulsatility - optional

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* between 18-60 years-old
* major depressive disorder, confirmed by Mini International Neuropsychiatric Interview (MINI)
* no bipolar disorder or schizophrenia, confirmed by MINI
* no neurological dementia disease
* able to perform olfactive tests, i.e. no anosmia and/or allergy to odors
* score MADRS (Montgomery AsbergDepression Rating Scale) \>20
* no antidepressant treatment during 14 days before inclusion
* informed written consent
* affiliation to a social security system

Exclusion Criteria

* patient who don't want any antidepressant treatment for this depressive episode
* legal incapacity and/or any circumstances making the person unable to understand the trial features, purposes or consequences
* participating to drug clinical study or in exclusion period of clinical study because of previous participation
* pregnant woman
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Tours

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wissam El-Hage, PhD

Role: PRINCIPAL_INVESTIGATOR

CHRU TOURS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Tours

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Desmidt T, Dujardin PA, Brizard B, Remenieras JP, Gissot V, Dufour-Rainfray D, Atanasova B, Kazour F, Belzung C, Camus V, El-Hage W. Decrease in ultrasound Brain Tissue Pulsations as a potential surrogate marker of response to antidepressant. J Psychiatr Res. 2022 Feb;146:186-191. doi: 10.1016/j.jpsychires.2021.12.056. Epub 2022 Jan 3.

Reference Type RESULT
PMID: 34995994 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PHAO16-WEH/BIORESA

Identifier Type: -

Identifier Source: org_study_id